SECTION I · THE BRIEF
Brief #40268Updated 27 AUG 2026WATERTOWN, MAGreenhouseMEDICAL ORGANIZATIONS
Employbl Company Profile

Director, Business Development

Kymera Therapeutics, Inc. operates as a biopharmaceutical company. The Company focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the…

Location
Watertown, MA
Company size
253–253
Posted
6d ago
Comp band
$195K–$275K
Section II · Full ProfileFree with an account
  • 01Equity package & total comp detailLocked
  • 02Seniority & experience requirementsLocked
  • 03Interview process & rubricLocked
  • 04Hiring manager & team contextLocked
  • 05Growth trajectory in this roleLocked
  • 06Offer & decision timelineLocked

Free account · no card · 2 minutes

Kymera Therapeutics logo

Director, Business Development · Kymera Therapeutics

View company profile
Job title
Director, Business Development
Job location
Watertown, MA
Job description

Who we are:

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (formerly Twitter) or LinkedIn

 

How we work:

  • PIONEER: We are courageous, resilient and rigorous in our mission to improve patients’ lives through our revolutionary degrader medicines.
  • COLLABORATE: We value trust + transparency from everyone. Our goals are shared, our decisions data-driven and our camaraderie genuine.
  • BELONG: We recognize our differences, inviting curiosity and inclusivity, so that our people are valued, seen, and heard.

                                                                                                                                                                                

How you’ll make an impact:

  • Drive Kymera's business development strategy, positioning our targeted protein degradation platform and pipeline at the center of strategic partnerships.
  • Identify, evaluate, and close strategic transactions with leading biopharma companies— spanning both buy- and sell-side opportunities.
  • Own transactions end to end, from initial opportunity through signature agreement, working closely with R&D, legal, finance, and outside counsel.
  • Lead and coordinate cross-functional diligence teams.
  • Prepare high-quality partnering materials, including presentations, term sheets, valuation models to support transaction processes.
  • Lead search and evaluation processes for prioritized external opportunities.
  • Develop financial analyses, including forecasts, comparables, and NPV valuations, to inform critical decisions.
  • Lead negotiation and execution of collaboration agreements (licensing and collaboration agreements, SRAs, MTAs, and CDAs) in close partnership with internal and external council.
  • Represent Kymera in the industry, building relationships with BD counterparts at current and potential partner companies
  • Represent Kymera at partnering conferences and industry events (eg. JPM, BIO) to build and maintain relationships with potential partners and support S&E activity.

 

Skills and experience you’ll bring:

  • An advanced degree — PhD, MD, or MBA — that reflects both scientific fluency and business acumen.
  • 8+ years of experience in business development, corporate development, or strategy consulting in biopharma.
  • Experience across the full deal lifecycle: sourcing, diligence, negotiation, and structuring.
  • Demonstrated success working with cross-functional teams and managing multiple concurrent projects
  • Strong strategic judgment, the ability to work independently and represent Kymera externally
  • NPV modeling, forecasting, and comparables analysis with the ability to communicate results clearly.
  • A track record of evaluating opportunities from both a scientific and commercial perspective.
  • Working knowledge of biopharma R&D (experience with small molecules is a plus), clinical development, and regulatory pathways
  • Excellent negotiation, written, and presentation skills.

 

Equal Employment Opportunity

Kymera Therapeutics is proud to be an equal opportunity employer, seeking to create a welcoming and diverse environment.  All applicants will receive consideration for employment without regard to race, color, religion, creed, gender, national origin, age, disability, veteran status, pregnancy, sex, marital status, gender expression or identity, genetic information, sexual orientation, citizenship, or any other legally protected class.

 

Compensation

  • Kymera offers a competitive compensation package that recognizes both results and capabilities through market-based, performance-driven pay.
  • The anticipated base salary range for this role is $195,000 – $275,000, with eligibility for annual bonus, equity participation, and comprehensive benefits.
  • Actual salary is based on a holistic evaluation of the specific role/level as well as each candidate’s depth of experience and the capabilities they bring to the position.

 

 

View job listing ↗
The Saturday Briefing

Get the Saturday tech briefing

New company profiles, funding moves, and who’s hiring across the market — every Saturday morning.

Where this role is based

Watertown, MA

Loading map…

Kymera Therapeutics headquarters

Watertown, MA

Company size

253253 employees

Founded

2017

Total raised

$1,956,800,000

View company profile ↗

Funding rounds

  • Post Ipo Equity$602M
  • Post Ipo Equity$250.8M
  • Post Ipo Equity$225M
  • Post Ipo Equity$275M
  • Post Ipo Equity$150M

    BVF Partners, Rock Springs Capital, Avoro Capital Advisors, EcoR1 Capital +2 more

  • Post Ipo Equity$257M
  • Series C$102M

    BVF Partners, Redmile Group, Bain Capital Life Sciences Fund, Wellington Management +9 more

  • IPOUndisclosed
  • Series B$65M

    6 Dimensions Capital, Bessemer Venture Partners, Pfizer Venture Investments, Aju IB Investment +6 more

  • Series A$30M

    Atlas Venture, Lilly Ventures, Amgen